An observational, cross-sectional, multicenter study assessing the quality of life (QoL) and health care resource utilization of patients being prescribed with sacubitril/valsartan in Portugal
Latest Information Update: 19 Nov 2020
At a glance
- Drugs Sacubitril/valsartan (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- Acronyms PRiMe
- 19 Nov 2020 Results (n=285; as of July 2020) assessing persistence of sacubitril/valsartan in a real-world setting of heart failure (HF) patients at 12 months, presented at the 23rd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
- 06 Nov 2019 Results (n=262; as of May 2019) assessing the prescription patterns and titration of Sacubitril/Valsarta were presented at the 22nd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
- 06 Nov 2019 Results assessing the robustness of self-assessed NYHA by correlating it with patients HF symptoms presented at the 22nd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research